Neurotech expands exclusive license to include all neurological disorders
Neurotech International Limited (ASX:NTI) has expanded its exclusive license with Dolce Cann Global Pty Ltd to now include all neurological disorders, disease or affliction affecting the human brain function, specifically - Autism, Epilepsy, ADHD, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, Transverse Myelitis, Inflammatory Brain disease, Fibromyalgia, Chronic Fatigue and Migraine.
It comes just as the company announced that it had secured $3.56M in funding, having completed an oversubscrib ed placement of $2M (before costs). These funds will be used to execute its existing business plan including the continued development and marketing of its Mente device along with research into the use of cannabinoids to treat neurological disorders including autism and ADHD
The latest clinical research clearly validates that inflammation, and more specifically neuroinflammation - is a well-recognised common feature in all neurological disorders.
Based on the scientific data generated in Neurotech’s studies to date, its NTI/Dolce full spectrum medicinal cannabis strains reigns superior to CBD alone when it comes to its powerful, neuro-modulatory, anti-inflammatory and neuro-regulatory mode of action.
NTI/Dolce stains possess activity up to 80% more potent than CBD alone and can regulate the suppression of inflammation via the suppression of the Arginase 1 pathway and beta- tubulin regulation which is a vital protein in the management of several neurological diseases such as Alzheimer’s disease, Huntington’s disease and Multiple Sclerosis.
The global market for neurology treatments is expected to grow to $39.4 billion by 2024. Rising prevalence of neurological diseases coupled with increasing awareness associated with the disease diagnosis in developing countries is assisting the market growth.
Commenting on this license expansion, Brian Leedman, Chairman of Neurotech International said, “The amendment of the Dolce Cann Global licence provides scope for the Company to expand our research programs beyond the current program with its focus on autism in children that is due to commence later this month”.
Deed of Variation Terms
In consideration for the licensors agreeing to vary the licence deed, the Company as licensee must issue 15,000,000 shares to Dolce Global or its nominee within 45 Business Days after the date of the deed (1 March 2021), and a further 15,000,000 shares to Dolce Global or its nominee within 45 Business Days after the Company successfully completes a small-scale clinical trial based on a neurological disorder (excluding Autism, Epilepsy or ADHD) within two years after the date of this deed.
The initial tranche of 15,000,000 shares will be issued under the Company’s remaining placement pursuant to ASX Listing Rule 7.1. The Company intends to seek shareholder approval for the issue of the second tranche of 15,000,000 shares.
Neurotech to commence clinical study program
Following the company’s successful in vitro findings, Neurotech has begun designing a phase I/II study to assess the safety and efficacy of the novel NTI/Dolce strain in a paediatric population.
The company has been engaging with international clinical experts in the field of translational medicinal cannabis to also assess the efficacy of the Mente device when used in combination with the novel NTI/Dolce medicinal cannabis strains.
If successful, this combination of the cannabis strains and the Mente device has the potential to be a “world-first” in the management of neurological diseases.
Neurotech is on-track to initiate its phase I/II clinical program through Monash Children’s Hospital toward the end of this current quarter.
Read a comprehensive overview including company’s cannabis strains and development strategy: Neurotech’s key near-term objectives.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.